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Improving Outcomes After Stroke By LEAPS (Locomotor
Experience Applied Post-Stroke) and Bounds
Steven C. Cramer, MD
Stroke is a chronic, lasting condition. Over 795 000 personshave a new stroke each year.1 The vast majority survive,
with those in the seventh decade living an average of 7 years
thereafter,1 most with some form of loss of function and
limitation of activity.2 Increasing evidence suggests that these
deficits are not fixed, but instead that the brain is plastic, that a
number of different therapies have the potential to improve brain
structure and function once the acute stroke period passes and
stroke injury is fixed, and that this plasticity can reduce post-
stroke disability.
Brain plasticity is facilitated by repeated practice. This is
true during development, during learning, in times of health,
and after brain injury such as stroke. This principle is the
foundation of poststroke treatments applied across behavioral
modalities such as neglect, aphasia, or weakness. Evidence
suggests that the responsiveness of the brain to such inter-
vention declines with time poststroke.3 However, many pa-
tients long past stroke can nonetheless benefit from repeated
practice such as with an activity-based regimen that is
initiated even months after stroke onset. For example, the
Extremity Constraint Induced Therapy Evaluation (EXCITE)
trial was a landmark study that found that constraint-induced
therapy improved upper extremity motor function when
initiated 3 to 9 months after stroke onset.4
It is in this context that the Locomotor Experience Applied
Post-Stroke (LEAPS) trial was initiated. The LEAPS trial
focused on improving gait after stroke by comparing 2 different
activity-based therapies and 2 different time points. Gait is
a priority because it is commonly affected by stroke, gait
improvements after stroke are linked to better quality of life,5
and hemiplegic patients rank recovery of gait as their top
priority.6 Importantly, gait velocity is linked to level of social
participation.7 A typical adult comfortable gait velocity is 3 to 4
mph, or 1.3 to 1.8 m/s. After stroke, a gait velocity that is 0.8
m/s is associated with full community mobility; 0.4 to 0.8 m/s
with short walks in the community; and0.4 m/s with mobility
limited to the home. Gait velocity thus has special value as an
end point because, in the vernacular of the World Health
Organization International Classification of Functioning, Dis-
ability and Health, it is a measure of loss of body function that
has a clear and direct link to level of participation.
The LEAPS trial was performed at 6 US sites. A total of
4909 patients were screened to enroll 408. Entry criteria
included age at least 18 years, living in the community, and
2 months poststroke at the time of randomization. Subjects
needed to have leg weakness and a gait velocity0.8 m/s but
be able to walk at least 3 m even if with assistance.
At 2 months after stroke, patients were randomized to 1 of 3
gait training groups: (1) body-weight support treadmill training
starting 2 months poststroke; (2) body-weight support treadmill
training starting 6 months poststroke; and (3) a progressive home
exercise program managed by a physical therapist starting 2
months poststroke. In all cases, training included 36 sessions, 90
minutes in duration, spanning 12 to 16 weeks. Also, for all
subjects, the study intervention was in addition to usual care.
The primary outcome was the proportion of participants in
each group who at 1 year poststroke had an improvement in
functional walking ability, defined as the ability to walk
independently at 0.4 m/s for subjects with initially severe
gait impairment or at 0.8 m/s for subjects with initially
moderate gait impairment. Having the end point vary accord-
ing to baseline status is uncommon in acute stroke trials but
seems sensible in restorative stroke trials, in which expecta-
tions vary in relation to baseline status and where this
approach is more feasible given that a baseline assessment of
behavior can be consistently obtained.
Enrollees were well matched at baseline, with mean age 62
years, time poststroke 64 days, 71% confirmed as ischemic
stroke, and 99.5% with modified Rankin Scale score 2 to 4.
The rate of subject dropout ranged from 3% in Group 3 to
17% in Group 2. Baseline impairment of gait velocity was
severe (0.4 m/s) in just over half of subjects and moderate
(0.4 to 0.8 m/s) in the rest. Physical therapy outside study
procedures was received by 81.9% of enrollees, who received
an average of 25 such sessions.
The primary outcome of transition to a higher functional
level of walking 1 year poststroke was achieved by 52% of
enrollees with no significant difference among the 3 treat-
ment groups. Secondary end points such as change in gait
velocity, distance walked over 6 minutes (gait endurance),
and balance also did not differ between groups. Treatments
were overall comparable in terms of safety.
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What are some points learned from the LEAPS trial? First,
months after stroke onset, when our patients have generally
seen their therapy reduced or discontinued, a majority can
still experience significant behavioral gains, in this case in a
measure that is directly linked with community participation.
This is underscored by the study observation that at 6 months
after stroke, subjects in Groups 1 and 3, each of whom started
study therapy 2 months after stroke, had better scores than
subjects in Group 2 who had not yet begun study therapy. An
intervention started on the first day poststroke that improved
gait velocity in 52% of patients 12 months poststroke would
garner great praise; this is no less true when the therapy is
initiated weeks after stroke onset.
A second point learned from the LEAPS trial is that
initiating study therapy 2 months poststroke had the same
long-term effect as initiating therapy 6 months poststroke. It
remains to be clarified whether an earlier start would prove
superior, for example, if study therapy was initiated in the
first month after stroke, a time when the brain is maximally
galvanized for plasticity.3,8 Third, like in a recent study of
robotic therapy for postacute stroke patients,9 therapy pro-
vided outside of the study procedures complicates interpretation
of results. LEAPS was in part a study of usual care plus
body-weight support treadmill training versus usual care plus a
progressive home exercise program. Usual care was a variable
that the study authors could measure but could not control. This
issue is difficult to surmount when evaluating postacute stroke
therapies, although outside therapy might be more standardized
in some countries and in certain practice settings and can be
measured and treated as a covariate if desired.10
The current results are similar to a prior study of subjects
with spinal cord injury11 in that the data do not suggest a
boost in gains with body-weight support treadmill training.
Some might argue that treadmill results might vary with differ-
ent populations, for example, all LEAPS enrollees had been
admitted to an inpatient rehabilitation before enrollment; or with
a more intensive training regimen, which might improve out-
comes.12 Nonetheless, the current results support the LEAPS
trial authors’ conclusion that, as compared with body-weight
support treadmill training, “home exercise requires less expen-
sive equipment, its implementation requires a smaller number of
staff members, less training is required for physical therapists,
and patients are more likely to comply with the regimen.”
How might we build on these results? Patients were
selected on the basis of behavioral and demographic charac-
teristics, but a baseline measure of brain anatomy or physi-
ology13 such as corticospinal tract integrity14 might prospec-
tively distinguish responders from nonresponders. Behavioral
phenotype arises on the basis of many different brain states,
but only some brain states are likely to benefit from therapy.
Future studies might incorporate measures of brain injury or
neurophysiology into entry criteria. Such an approach might
reduce variance and so increase power in the clinical trial
setting or help maximize the efficiency with which rehabili-
tation resources are used in the clinical practice setting.
A number of restorative therapies are under study to improve
outcomes after stroke. Would behavioral gains in the LEAPS
trial have been greater if interventions were accompanied by a
pharmacological or cell-based therapy? Future studies might
examine such a proposal, because favorable preclinical and early
clinical results exist for a number of candidate therapies.15,16
The LEAPS investigators are to be congratulated for complet-
ing a challenging study, over an extended follow-up period, in a
cohort that was at a time poststroke that has sometimes received
less attention. Sound study design such as matched intensity of
intervention across treatment arms and use of an active control
group increases the clarity of the message. There was no
“nontherapy” control group, and so it is difficult to precisely
determine which findings are attributable to usual care alone.
LEAPS is 1 of a growing number of studies that relies on
modality-specific end points, an approach that may be of
particular value for restorative therapies.17 Overall, LEAPS
provides insight into the optimal therapy for improving gait after
stroke and reminds us of the enormous potential for brain
plasticity that exists in patients beyond the acute phase of stroke.
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